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Purpose: The factors that lead to myointimal hyperplasia (MH) in arterial vein grafts 
(AVGs) are unknown. Platelet-derived growth factor (PDGF) and basic fibroblastic 
growth factor (bFGF) are two powerful mitogens for smooth muscle cells that have been 
implicated in the genesis of MH. The aim of this study was to analyze the correlation 
between progression and regression of MH and production of PDGF and bFGF in 
experimental vein grafts. 
Materials: In 64 inbred Lewis rats, a 1-cm segment of inferior vena cava was inserted at the 
level of the abdominal aorta. The segments of inferior vena cava were obtained from 
syngenic rats. In 48 rats, the AVG was explanted 3 days (n = 8), 7 days (n = 8), 4 weeks 
(n = 24), and 12 weeks (n = 8) after surgery. In 16 rats the vein graft was explanted after 
being in the arterial system for 4 weeks and was reimplanted as a venous-venous bypass in 
syngenic Lewis rats. Reimplanted vein grafts (RVGs) were explanted 2 weeks (n = 8) and 
8 weeks (n = 8) later. Grafts were analyzed by light and electron microscopy, morphom- 
etry, and histochemistry, and were put in organ culture to assess PDGF and bFGF 
production and mitogenic activity. 
Results: We observed MH formation in AVGs and MH regression in RVGs (p < 0.001). 
PDGF and bFGF production correlated with the degree of MH (p < 0.01). Histochem- 
istry showed PDGF and bFGF in the area of MH in AVG, which disappeared in RVG. 
Conditioned media from AVG had greater mitogenic activity than RVG or control veins. 
Conclusions: MH formation and regression in experimental vein grafts correlate with 
PDGF and bFGF production. (J VASC SURG 1996;23:568-75.) 
Despite the durability of the autogenous saphe- 
nous vein graft, the incidence of thrombosis at the end 
of the first year in the coronary and lower-extremity 
circulation ranges fi'om 20% to 50%. 13 Many of these 
failures result from the development of vein graft 
stenosis, which is often caused by myointimal hyper- 
plasia (MH). 4,s 
In 1906, Carrel and Guthrie 6observed that vein 
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grafts, once implanted in the arterial circulation, adapt 
by undergoing wall thickening. The formation of 
intimal thickening depends on smooth muscle cell 
(SMC) proliferation and migration and on matrix 
synthesis.7 The factors that lead to MH in arterial vein 
grafts (AVGs) are not well-defined. Several hemody- 
namic factors that could explain vein-graft MH have 
been identified: reduced flow velocity and shear 
stress, 8 tangential stress, 9 and increased eformation 
of the vein wall in the circumferential direction. ~~ 
Preexisting vein disease could be responsible for MH 
in some cases, t3 The biologic mechanisms leading to 
MH in vein grafts implanted in the arterial circulation, 
however, are not known. 
Two of the best-analyzed mitogens for SMCs are 
platelet-derived growth factor (PDGF) ~4 and basic 
fibroblastic growth factor (bFGF).ls PDGF was origb 
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nally identified from human platelets, but other types 
of cells were found to be able to release PDGF-Iike 
molecules, including endothelial cells (ECs) and 
SMCs. Pure PDGF was described as a 27- to 31-KD 
glycoprotein that was thought o exist as a dimer of  
two distinct but highly similar polypeptides, which 
were termed A chain and B chain. 16"17 PDGF is a 
major mitogen for connective tissue cells.~8'~9 bFGF is 
a member of the heparin-binding mitogens and is 
ubiquitously distributed.~S 
The principal animal model that has been used to 
study MH is balloon angioplasty of the normal rat 
artery. Ferns et al. 2~ demonstrated that the develop- 
ment of  an intimal lesion induced by intraarterial 
balloon catheter was reduced 40.9% by administra 
tion of the antibody to PDGF. Analysis of segments of 
primary and restenotic human lesions obtained with 
in-situ hybridization after atherectomy has demon- 
strated increased expression of PDGF. 2~ Lindner and 
Reidy 22 showed that bFGF is a potent pharmacologic 
stimulant of SMC growth in injured arteries. They 
demonstrated that the administration of a blocking 
antibody to bFGF inhibits the proliferation of SMCs 
in balloon-injured arteries by 80%. The results of their 
study suggest that endogenous bFGF is a major 
mitogen that controls the growth of vascular SMCs 
after injury. 
Theoretically, PDGF and bFGF could be respon- 
sible fbr MH formation in AVGs. The purpose of this 
study was to determine the production of PDGF and 
bFGF by vein grafts when inserted into the arterial 
circulation and by AVGs when reimplanted in the 
venous system. 
MATERIAL  AND METHODS 
Experimental design and operative proce- 
dures. Male inbred Lewis rats with an average weight 
of  250 gm were used in the study. In 64 rats, 1-cm 
segments of inferior vena cava that had been obtained 
from syngenic rats were implanted at the level of  the 
abdominal aorta. In 48 rats, the AVG was explanted 3 
days (n = 8), 7 days (n = 8), 4 weeks (n = 24), and 12 
weeks (n = 8) after surgery. In 16 rats the vein graft 
was explanted after 4 weeks in the arterial system and 
was reimplanted as a venous-venous bypass in syn- 
genie Lewis rats. Reimplanted vein grafts (RVG) were 
explanted 2 weeks (n = 8) and 8 weeks (n = 8) later. 
At the time of harvest, segments of  similar dimensions 
of endogenous inferior vena cava aorta above and 
below the graft were removed. 
The animals were anesthetized with intramuscular 
xylazine (3 mg/kg) and intramuscnlar ketamine (50 
mg/kg) supplemented by intraperitoneal ketamine 
for maintenance. Surgery was performed with an 
operating microscope (Zeiss OPMI 7-D; Carl Zeiss, 
Inc.; Thornwood, N.Y.). A 1-cm segment of  supra- 
diaphragmatic inferior vena cava was obtained from 
donor rats. The chest was opened, and the supradia- 
phragmatic portion of the inferior vena cava was 
identified and excised. The rat was killed with an 
overdose of anesthetic. The vein was kept in Dulbec- 
co's modified Eagle's medium (DMEM) for approxi- 
mately 20 minutes while the receiving rat was anes- 
thetized, the abdominal aorta identified, and both 
proximal and distal control specimens obtained. The 
vein grafts were inserted with end-to-end anasto- 
moses using 10-0 nylon sutures (Ethicon Inc.; Som- 
erville, N.J.) in a continuous fashion. 
In the RVG group, the AVG was harvested after 
being in the arterial system for 4 weeks and was 
reimplanted with the same microsurgical procedures 
and methods at the level of the left iliac vein with 
end-to-end anastomoses. The patency of the grafts 
was evaluated at the time of surgery and was evaluated 
thereafter by weekly palpation of  the femoral pulse 
and inspection for leg swelling. 
Animal care complied with the "Principles of 
Laboratory Animal Care" as formulated by the Na- 
tional Society for Medical Research and the Guide for 
the Care and Use of Laboratory Animals (NIH Pub 
lication No. 86-23, revised 1985). 
At the time of harvest, the abdomen and chest 
were opened with the animal under deep anesthesia. 
The aorta or the left iliac vein above and below the 
graft, the vein graft, and a segment of the same 
dimensions of the supradiaphragmatic inferior vena 
cava were exposed and excised. The rat then was killed 
with an overdose of anesthetic. Three grafts from each 
group were divided in segments and processed for 
light and electron microscopy and histochemistry. 
Five grafts for each group were studied for PDGF and 
bFGF. 
Histology. Segments of grafts were fixed in 
formaldehyde. Following standard procedure, the 
specimens were stained with hematoxylin and eosin. 
Intimal and medial areas were calculated by video- 
morphometry (Quantimet 500) at different levels. 
For scanning electron microscopy, specimens were 
fixed in 2.5% glutaraldehyde made up in 0.1 mol /L  
cacodylate buffer (pH, 7.2), rinsed several times, and 
left for 1 hour in the same buffer. Next, the specimens 
were fixed in osmium 1% for 1 hour, dehydrated in
ascending concentrations of ethanol (15% to 
100%), critical point-dried in CO2, mounted in 
specimen stubs, and sputter coated with gold-palla- 
dium according to standard technique. All specimens 
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Table I. Intima-media area (~.lm 2• 10 s) 
Control vein 1.9 _+ 0.8 
AVG 
3 days 6.4 + 2.4 
7 days 13.1 + 4.1 
4 weeks 16.8 + 4.4 
12 wccks 17.5 + 3.6 
RVG 
2 weeks 15.0 + 6.0 
8 weeks 5.9 -+ 3.3 
were examined in a scanning electron microscope 
(Hitachi S 570; Tokyo) at the accelerating voltage of 
15 kV. 
Histochemistry. Tissues were prepared tbr im- 
munohistochemical analysis of bFGF, PDGF, and 
~-actin with fi'ozen section techniques to guarantee 
accessibility to intracellular antigens as previously 
described. 23Briefly, individual sections were made 
within the midportion of the vein graft and control 
vein with a 1720 Digital MGW Lauda cryostat (Leitz; 
Wetzlar, Germany) and placed on gelatin-coated glass 
slides. Sections were fixed in cold methanol, rehy- 
drated, absorbed with normal mouse serum to block 
nonspecific binding of  reagents, and treated with 4% 
H202 to eliminate ndogenous peroxidase. Sections 
were covered with primary mouse monoclonal anti- 
bodies anti-bFGF and anti-tx-actin (Sigma Chemical 
Co; St. Louis) and rabbit polyclonal antibodies anti- 
PDGF, followed by goat anti-mouse immunoglobu- 
lin G and goat anti-rabbit mmunoglobulin G conju- 
gated to horseradish peroxidase (Sigma) fbr amplifi- 
cation. Peroxidase localization was visualized with 
diaminobenzidine.2"~ Control sections were treated in 
an identical manner except hat nonspecific immuno- 
globulin G antibodies were used. 
Organ culture. The arterial and vein grafts and 
the aortic segment above and below the graft (five 
grafts ti-om each group) were opened longitudinally 
and rinsed thoroughly tbr 10 minutes with DMEM 
supplemented with antibiotics (gentamicin 200 
btg/ml, streptomycin 100 btg/ml, penicillin 100 
IU/ml) .  The specimens were placed in 48-well Cos- 
tar (Costar Corp.; Cambridge, Mass.) tissue culture 
plates fbr organ culture. The tissue was incubated for 
5 days at 37 ~ C in a 5% CO 2 atmosphere. Aliquots of 
conditioned media were collected at 72 hours and 
centrifuged fbr 5 minutes at 15,000 rpm, and the 
supernatant was stored at -80 ~ C for assay of mito- 
genie activity and assay for PDGF and bFGF release. 
Assay for mitogenic activity. Swiss 3T3 cells 
were plated in 96-well plates (Falcon Plastic, Oxnard, 
Calif.) at a density of 4 • 104 cells/ml in 200 ~tl 
DMEM supplemented with 0.1% f~tal calf serum. 
Seventy-two hours later conditioned serum free me- 
dia from AVG and RVG were added to Swiss 3T3 cells 
(20 ~tl). Positive control specimens received an 
equivalent volume of DMEM plus human recombi- 
nant bFGF (20 ng/ml)  or human recombinant 
PDGF (50 ng/ml;  Bochringer Mannheim; Man- 
nheim, Germany); negative control specimens re- 
ceived only DMEM. After 2 days, tritiated thymidinc 
(0.5 ~Ci per well plate) was added, the cultures were 
incubated for 18 hours and collected on Skatron 
filters (Skatron Instruments; Sterling, Va.) for radio- 
activity determination i  an LKB (LKB Instruments, 
Inc.; Gaithersburg, Md.) scintillation counter. 
Reduction o f  mitogenic activity. Measurement 
of Swiss 3T3 cells' DNA synthesis-stimulating activity 
of the conditioned media from AVG and RVG was 
repeated in the presence of an excess of antibodies to 
PDGF AA and PDGF BB (50 btg/ml; Genzyme Co; 
Boston, Mass.) and in the presence of monoclonal 
antibody to bFGF (produced in our laboratory). 
Tritiated thymidine was again added and cultures 
were incubated fbr 18 hours. After further processing, 
the radioactivity was measured. 
Assay o f  PDGF and bFGF in condit ioned 
media. The presence of bFGF and PDGF molecules 
in serum-fi'cc onditioned media from AVG, RVG, 
and aortic segments was determined by inhibition 
antibody-binding assay. A dilution of anti-bFGF 
mouse monoclonal antibody that showed 50% maxi 
mal reactivity against bFGF was incubated with vari- 
ous dilutions of conditioned media in 400 lal tubes 
precoatcd with phosphate- buffered saline (PBS) gela- 
tin 2%. After 20 hours of incubation at 4 ~ C, Staphy- 
lococcus aureus-protein A was added, and the immu- 
noaggregates were removed by centrifugation. The 
residual antibody-binding activity in the supernatant 
was measured by enzyme-linked immunosorbent as- 
say. Plastic wells (96 wells, Falcon Plastic) were coated 
with bFGF ( 10 ng per well) for 8 hours at 4 ~ C. Plates 
then were washed twice with PBS solution and 
saturated with PBS gelatin 1% for 2 hours at 37 ~ C. 
Washed wells were then filled with 50 lal per well of 
supernatant obtained after immunoprecipitation. Af 
ter 2 hours of incubation at 37 ~ C, the wells were 
washed with PBS gelatin 0.1%. Peroxidase-labeled 
goat anti-mouse immunoglobulin antibody was 
added. After 60 minutes of incubation at 37 ~ C, the 
plate was washed three times in PBS gelatin 0.1% and 
once in distilled water. Finally o-phenylenediaminc 
dihydrochloride 0.4 mg/ml  (Sigma Chemical Co.; 
St. Louis) was added as substrate for the enzyme. 
Bound specific antibody was quantitatively measured 
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Fig. 1. Transverse ction of control vein (A) and ofAVG (B) 4 weeks after surgery (original 
magnification, • Muscle-specific ~x-actin demonstrated that SMCs formed the area of MH 
of AVG. L, lumen. 
Fig. 2. Localization ofbFGF in control ungrafted vein (A) and in AVG (B) 4 weeks after surgery 
(transverse section; original magnification, x400). A shows no localization detectable for bFGF 
in control ungrafted veins. B shows localization ofbFGF in SMCs of AVG. L, lumen. 
by optical density reading at 492 nm with a spectro- 
photometer (Beckman Instruments, Inc.; Palo Alto, 
Calif.). The amount of bFGF in the conditioned 
media was determined with a reference curve ob- 
tained with known quantities of human recombinant 
bFGF. We used mouse anti-bFGF monoclonal anti- 
body as the positive control and antibody without 
specificity as the negative control. Similar experiments 
were used to determine the presence and amount of 
PDGF in the conditioned media. 
Statistical analysis. We used the ~(2 test, analysis 
of variance, and Student's t test where appropriate. 
Data were expressed as mean + SD. Differences were 
considered significant at the 5% critical level. 
RESULTS 
Structural  changes. At harvest AVGs were firm 
and rigid when compared with control veins. Micro- 
scopically, intact ECs were present on the surface of 
AVG and RVG and in the control vein. Scattered 
platelcts and leukocytes adhered to ECs. MH was 
present in all arterialized vein grafts. Large amounts of 
connective tissue and several layers of SMCs were also 
present. In the RVGs, connective tissue was prepon- 
derant over SMCs. Control veins consisted of a single 
layer of  ECs and a few layers of  SMCs. 
Table I shows the total area of intima and media 
(~tm 2) ofAVGs, RVGs, and control veins. In AVGs, 
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Fig. 3. Localization of PDGF in control ungrafted vein (A) and in AVG (B) 4 weeks after 
surgery (transverse section; original magnification, • Localization of PDGF in SMCs of 
AVG is evident. L, lumen. 
intima-media rea increased significantly with time. 
Two weeks after reimplantation, RVGs showed a 
decrease in the total area of intima and media when 
compared with the AVGs; the difference became 
significant after 8 weeks (p < 0.05). 
Histochemistry. Histochemistry showed that the 
area of MH in AVG was composed of  SMCs that were 
positive for ~-actin (Fig. 1 ). PDGF and bFGF, which 
were absent in both the control veins and RVGs, were 
present in the area of  MH in AVGs (Fig. 2 and Fig. 3). 
Mitogenic activity o f  condit ioned media. The 
conditioned media from AVG had more mitogenic 
activity than did the conditioned media from RVG or 
control vein (p < 0.001). This increased production 
ofmitogens could stimulate the growth of SMCs and 
lead to MH. 
Reduction o( mitogenic activity by anti-bFGF 
anti-PDGF antibodies uggests that the mitogenic 
activity is caused by that particular growth factor. 
Addition of a mixture of  anti-PDGF AA and anti- 
PDGF BB antibodies to the medium of 3T3 cell 
cultures exposed to conditioned medium from AVG 
decreased the uptake of tritiated thymidine by an 
average of 25% (p < 0.001; Fig 4). Addition of an 
excess of anti-bFGF antibody to the medium of 3T3 
cell cultures exposed to conditioned medium from 
AVG decreased the uptake oftritiated thymidine by an 
average of 55% (p < 0.001; Fig 5). 
PDGF and bFGF assay by enzyme-linked im- 
munosorbent assay. Table II shows the production 
of PDGF and bFGF by AVG, RVG, and control vein. 
AVG produced a higher quantity of" growth factors 
(p < 0.01). 
D ISCUSSION 
Once inserted in the arterial circulation, vein 
grafts show diffuse MH and wall thickening. In the 
rabbit experimental model, MH did not develop in 
vein segments implanted in the venous circulation, 
which suggests that the arterial environment and not 
surgical manipulation is required for the formation of 
this lesion. 24 
Davies et al?4 performed common carotid vein 
bypass in rabbits. MH developed in all grafts and 
regressed significantly after the vein grafts were reim- 
planted in the venous circulation. In a similar study, 
Fann et al. 25 showed that MH in vein grafts regresses 
significantly when a graft implanted in the arterial 
circulation for 12 weeks is reimplanted in the venous 
system and harvested after an additional-12 weeks. 
Our study revealed similar findings. How does arterial 
flow influence the formation ofMH? Berguer et al) ~ 
showed that in AVGs, MH is more evident in areas of" 
low flow velocity. Similar results were found by 
Dobrin et al., ~ who fbund that MH in AVGs was 
associated with low flow velocity and a high degree of 
circumferential deformation. Morinaga et 311.26 found 
an increased egree of MH in AVGs implanted under 
low flow conditions that regressed once the grafts 
were rcimplanted in a system with normal parameters 
of flow. Experiments with prosthetic arterial grafts 27'28 
showed a reverse relationship between high flow and 
high shear stress and the degree of MH. 
We found that vein grafts, once inserted in the 
arterial circulation, develop MH and produce a large 
quantity of growth factors, including PDGF and 
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Fig. 4. Mitogenic activity expressed for 1 cm 2 of graft 
surface (empty columns) and its reduction by anti-PDGF 
antibody (full columns). 
bFGF. Hypothetically, vein grafts develop MH to 
adapt to the new hemodynamic system. Increasing 
shear stress has been shown to promote the release of 
PDGF and bFGF by ECs and SMCs. Hsieh et al. 29 
showed that shear stress increases PDGF mRNA levels 
in ECs. Maiek et al.a~ demonstrated that laminar shear 
stress induced a significant increase of PDGF B and 
bFGF mRNA levels in ECs. They found that expres- 
sion of each peptide growth factor gene is differen- 
tially regulated by fluid shear stress. Resnick et al. 31 
found that shear stress determines expression of 
PDGF B in ECs by inducing transcription factors that 
interact with a common promoter element. The 
signal promoting that increases production of PDGF 
is ill-defined. Shear stress induction of PDGF and 
bFGF expression may depend on signal transduction 
mechanisms involving protein kinase C activation. 
Previous work has shown that shear stress timulates 
phosphoinositide turnover in ECs, producing the 
second messengers inositol triphosphatc and diacyl- 
glycerol, which stimulate protein kinase C activity. "~2 
These growth factors may be responsible for MH 
through aparacrine/autocrine m chanism. Although 
macrophages and leukocytes may produce PDGF and 
g 
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Fig. 5. Mitogenic activity expressed for 1 cm 2 of graft 
surf~tce (empty columns) and its reduction by anti-bFGF 
antibody (full columns). 
Table II. Growth factor production 
(ng/cm2/72 hr) 
PDGF bFGF 
Contro l  vein 11 + 3 55 + 7 
AVG 
3 days 33 + 5 128 _+ 9 
7 days 45 _+ 7 153 + 11 
4 weeks 69 + 8 295 _+ 20 
12 weeks 65 + 9 340 + 18 
RVG 
2 weeks 39 -+ 9 86 + 10 
8 weeks 13 + 3 92 _+ 12 
bFGF, neither of these cell types appeared to account 
for the differences observed in PDGF and bFGF 
release between vein grafts and control veins; ECs and 
SMCs probably are the source of these growth factors. 
It is evident hat ECs and SMCs can release growth 
factors and sustain their own growth. 
PDGF and bFGF most likely represent a central 
factor in the development of MH in AVGs. Experi- 
mental studies support this hypothesis. Several re- 
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ports have demonstrated increased expression of 
PDGF in association with naturally occurring athero- 
sclerosis, experimentally induced MH,  and MH that 
was associated with thilure of vascular grafts. PDGF 
BB, when infused into rats subjected to balloon 
carotid injury, produced a two- to threefold increase 
in medial SMC proliferation. More importantly, 
PDGF BB greatly increased (20-fbld) the intimal 
thickening and migration of SMCs from the media to 
the intima during the first 7 days after injury. 33 
Administration of polyclonal antibodies to PDGF 
resulted in a 40.9% reduction in the area of MH 
induced by intraarterial balloon catheter injury in 
athymic nude rats. 2~ A similar ole has been attributed 
to bFGF. It has been shown that the proliferation of 
SMCs is significantly reduced in animals that receive 
blocking ant i -bFGF antibodies before balloon angio- 
plasty. 22 
CONCLUSION 
Many studies have supported a role fbr PDGF and 
bFGF in the genesis of MH and atherosclerosis. In our 
study we found that AVGs produce agreater quantity 
of growth fhctors. This phenomenon could represent 
the cause fbr the high incidence of stenotic hanges 
seen in saphenous vein bypass grafts. 
The results of our study support the view that 
pharmacologic intervention directed to reduce 
growth factor production might be beneficial in 
preventing stenotic hanges in saphenous vein bypass 
grafts. 34 
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